Search research articles
Contact Us
Filters
Showing results (291-300 of 347) with videos related to
Page
of 35
Sort By:
Haematologica
|
August 2, 2014
MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis
Axel Benner, Larry Mansouri, Davide Rossi, et al.
Plos Genetics
|
April 18, 2013
Epigenetic upregulation of lncRNAs at 13q14.3 in leukemia is linked to the In Cis downregulation of a gene cluster that targets NF-kB
Angela Garding, Nupur Bhattacharya, Rainer Claus, et al.
Blood Advances
|
December 22, 2020
Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication
Nikolaus Jahn, Tobias Terzer, Eric Sträng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 14, 2011
FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma
Marc Remke, Thomas Hielscher, Andrey Korshunov, et al.
Blood
|
October 2, 2014
Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation
Richard F Schlenk, Sabine Kayser, Lars Bullinger, et al.
Journal of Behavioral Medicine
|
March 5, 2025
Worry about prostate cancer and risk perception among middle-aged men: results from the PROBASE trial
Valentin H Meissner, Andreas Dinkel, Martina Kron, et al.
Haematologica
|
April 3, 2016
Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy
Marie-Luise Hütter-Krönke, Axel Benner, Konstanze Döhner, et al.
Leukemia
|
August 3, 2022
Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial
Nikolaus Jahn, Ekaterina Jahn, Maral Saadati, et al.
European Urology Oncology
|
July 10, 2025
Do We Need Early Detection of Grade Group 2 Prostate Cancer in a Screening Program for Young Men? Results from the PROBASE Screening Trial
Peter Albers, Agne Krilaviciute, Petra Seibold, et al.
Hemasphere
|
July 16, 2024
Refinement of the prognostic impact of somatic <i>CEBPA</i> bZIP domain mutations in acute myeloid leukemia: Results of the AML Study Group (AMLSG)
Frank G Rücker, Andrea Corbacioglu, Julia Krzykalla, et al.
Page
of 35
Search research articles
Search
Showing results (291-300 of 347) with videos related to
Sort By:
Page
of 35
Haematologica
|
August 2, 2014
MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis
Axel Benner, Larry Mansouri, Davide Rossi, et al.
Plos Genetics
|
April 18, 2013
Epigenetic upregulation of lncRNAs at 13q14.3 in leukemia is linked to the In Cis downregulation of a gene cluster that targets NF-kB
Angela Garding, Nupur Bhattacharya, Rainer Claus, et al.
Blood Advances
|
December 22, 2020
Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication
Nikolaus Jahn, Tobias Terzer, Eric Sträng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 14, 2011
FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma
Marc Remke, Thomas Hielscher, Andrey Korshunov, et al.
Blood
|
October 2, 2014
Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation
Richard F Schlenk, Sabine Kayser, Lars Bullinger, et al.
Journal of Behavioral Medicine
|
March 5, 2025
Worry about prostate cancer and risk perception among middle-aged men: results from the PROBASE trial
Valentin H Meissner, Andreas Dinkel, Martina Kron, et al.
Haematologica
|
April 3, 2016
Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy
Marie-Luise Hütter-Krönke, Axel Benner, Konstanze Döhner, et al.
Leukemia
|
August 3, 2022
Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial
Nikolaus Jahn, Ekaterina Jahn, Maral Saadati, et al.
European Urology Oncology
|
July 10, 2025
Do We Need Early Detection of Grade Group 2 Prostate Cancer in a Screening Program for Young Men? Results from the PROBASE Screening Trial
Peter Albers, Agne Krilaviciute, Petra Seibold, et al.
Hemasphere
|
July 16, 2024
Refinement of the prognostic impact of somatic <i>CEBPA</i> bZIP domain mutations in acute myeloid leukemia: Results of the AML Study Group (AMLSG)
Frank G Rücker, Andrea Corbacioglu, Julia Krzykalla, et al.
Page
of 35